Clinical Trials Directory

Trials / Unknown

UnknownNCT00070733

The Effect of 5-Alpha Reductase on Testosterone in Men

The Role of 5-Alpha Reductase in Mediating Testosterone Actions

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
184 (planned)
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · NIH
Sex
Male
Age
21 Years – 40 Years
Healthy volunteers
Accepted

Summary

The enzyme 5-alpha reductase is present in small amounts in muscle and converts testosterone to dihydrotestosterone (DHT). Testosterone affects lean body tissue, muscle size, muscle strength, and sexual function in men. This study will evaluate how 5-alpha reductase influences the effects of testosterone in young healthy men.

Detailed description

Testosterone, the predominant circulating androgen in men, serves as the active hormone in some target tissues; however, testosterone effects in other target organs require its conversion to two active metabolites, estradiol 17-beta and DHT. The role of 5-alpha reductase in mediating testosterone's effects on muscle and sexual function remains unclear. This study will determine whether 5-alpha reduction of testosterone to DHT is necessary for mediating effects on fat-free mass, muscle size, muscle strength, and leg power in men. The study will also evaluate the necessity of 5-alpha reductase for maintenance of androgen effects on sexual function (sexual desire, overall sexual activity, nocturnal penile tumescence \[NPT\], response to visual erotic stimulus, and penile rigidity) in men. Participants in this study will be treated with a drug to suppress endogenous testosterone production. Participants will then be randomly assigned to receive either testosterone and placebo or testosterone and the 5-alpha reductase inhibitor dutasteride. Testosterone will be administered weekly; dutasteride and placebo will both be administered daily. Diet and exercise will be standardized across both groups. Participants will be assessed at study entry and Week 20. Assessments will include measurements such as a DEXA scan, MRI scan, and muscle performance and sexual function tests. Participants will also have blood tests for safety monitoring; blood tests will include measures of hematocrit, liver enzymes (AST and ALT), prostate specific antigen (PSA), and cholesterol.

Conditions

Interventions

TypeNameDescription
DRUGtestosterone enanthate
DRUGduastride

Timeline

Start date
2003-08-01
Completion
2005-06-01
First posted
2003-10-10
Last updated
2005-11-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00070733. Inclusion in this directory is not an endorsement.